Preliminary Analysis Indicates That Oasmia's Product Candidate Paccal(R) Vet Met Primary Endpoint in Phase III Study in Dogs With Mastocytoma

Published: May 04, 2010

UPPSALA, Sweden, May 4, 2010 (GLOBE NEWSWIRE) -- Oasmia Pharmaceutical AB announced today the preliminary results from a clinical Phase III study of dogs affected by mastocytoma (mast cell tumours), a type of skin cancer. The study measured the effect of Paccal® Vet. Preliminary analysis of data supports the primary endpoint that clinical response of dogs treated with Paccal Vet was superior to the active control lomustine and that the frequency of side effects was comparable between the groups. As expected, Paccal Vet resulted in less liver dysfunctions than in the lomustine group.

Back to news